CLINICAL TRIALS PROFILE FOR VNRX-7145
✉ Email this page to a colleague
Clinical Trials for VNRX-7145
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04243863 ↗ | VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days. |
| NCT04243863 ↗ | VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Completed | Venatorx Pharmaceuticals, Inc. | Phase 1 | This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days. |
| NCT04877379 ↗ | VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024 (ceftibuten) when administered as single agents and with co-administration in a single dose cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8 hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for VNRX-7145
Condition Name
Clinical Trial Locations for VNRX-7145
Trials by Country
Clinical Trial Progress for VNRX-7145
Clinical Trial Phase
Clinical Trial Sponsors for VNRX-7145
Sponsor Name
